Answers are grounded in this paper and cite their sources.
Purpose: To identify routinely available factors associated with insulin requirement in women with gestational diabetes mellitus (GDM), focusing on prepregnancy body mass index (BMI) and serum C-peptide as clinical proxies of insulin resistance and β-cell secretory capacity. Methods: Retrospective cohort of 110 women with GDM meeting standard 75-g glucose tolerance test criteria, followed at a tertiary internal medicine clinic in Istanbul, Türkiye (2020–2023). Insulin was started when glycaemic targets were not met with medical nutrition therapy. Associations were examined by multivariable logistic regression with bootstrap validation. Results: Insulin was required in 45 women (40.9%), rising from 13.6% to 52.8% across prepregnancy BMI categories (P for trend = 0.003). After adjustment for age, glucose tolerance test values, HbA1c and referral timing, higher prepregnancy BMI (adjusted odds ratio [aOR] 1.18 per kg/m2; 95% confidence interval [CI] 1.06–1.31) and lower C-peptide (aOR 3.42 per halving; 95% CI 1.67–6.97) were independently associated with insulin requirement. Insulin need was 71.4% in women with both obesity and below-median C-peptide versus 8.7% in those with neither (aOR 24.5; 95% CI 4.3–139.7). Adding C-peptide increased the area under the curve from 0.76 to 0.82 (optimism-corrected 0.78). Insulin-treated women had more preterm births (aOR 6.01; 95% CI 1.01–35.65) and accounted for all cases of macrosomia. Conclusion: Prepregnancy BMI and C-peptide appear to capture complementary insulin-resistance and insulin-secretory pathways to insulin requirement in GDM. Combining these inexpensive measures at diagnosis may help identify women likely to need insulin; prospective validation is warranted.
No takes yet. Share an insight, caveat, or question.
Bozkurt et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: